Articles On Neuren Pharmaceuticals (ASX:NEU)

ASX health sector falls broader market with some key names ailing in reporting season CSL Phase III trial fails to meet primary efficacy endpoint but delivers solid H1 FY24 results Neuren Pharmaceuticals falls 13% on Friday after short sel...

It has been another busy week for Australia's top brokers. This has led to the release of a number of broker notes. Three broker buy ratings that you might want to know more about are summarised below. Here's why brokers think these ASX sh...

We had a team meeting this morning. We were discussing how to make sure our readers and members were best equipped to use our advice. Spoiler: some of the people who get grumpy with our advice are those who, ahem, don't actually follow it....

Neuren Pharmaceuticals (ASX:NEU) shares are tanking on news its US partner allegedly mischaracterised the safety of a drug for children The findings come from a short-selling firm That firm, Culper Research, reports the drug hospital...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are ending the week deep in the red. The ASX 200 healthcare share was down 13% to $20.04 before being paused from trade. What's going on with this ASX 200 healthcare share? Investors have been h...

The S&P/ASX 200 Index (ASX: XJO) has just given ASX investors a not-so-merry start to December today, closing the trading week with a mild loss....

The S&P/ASX 200 Index (ASX: XJO) was on form in November and charged higher. Over the period, the benchmark index rose 4.5% to finish the period at 7,087.3 points. While most ASX 200 shares climbed with the market, some stood out wit...

ASX health stocks flat in past five days in line with broader markets  Avita lowers full year 2023 guidance after slower progress in its customer’s VAC processes EBOS decides against acquisition of animal care business, reportedly Greencro...

ASX medical devices to make inroads with FDA after a good year for drug developers FDA is reviewing Allegra’s Spinal Cage Device made from 3D-printed Sr-HT-Gahnite Stockhead reached out to Allegra’s board member, Dr Nick Hartnell   It’s b...

Neuren Pharmaceuticals Ltd (ASX: NEU) shares are having a positive start to the week. In afternoon trade, the ASX 200 pharmaceutical stock is up almost 2% to $14.93. Why is this ASX 200 stock rising? The catalyst for the rise in Neuren's s...

On Friday, the S&P/ASX 200 Index (ASX: XJO) finished the week on a subdued note. The benchmark index fell 0.1% to 7,049.4 points. Will the market be able to bounce back from this on Monday? Here are five things to watch: ASX 200 expe...

ASX health stocks rise in past five days and outpace broader markets for second week All study visits complete in Neuren’s Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid Syndrome Ramsay Health Care after revealing that it has reach...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

At the $240 million Perennial Better Future Trust, healthcare stocks are a critical component of our ESG-focused portfolio. These stocks, many of which have global reach, have the potential to generate attractive returns while shaping a bet...

An additional news report on the recommendation, valuation, forecast and opinion changes and updates for ASX-listed equities. In addition to The Australian Broker Call Report, which is published and updated daily (Mon-Fri), FNArena has now...

Neuren Pharmaceuticals (ASX:NEU) has announced that its Phase 2 clinical trial of NNZ-2591 for Phelan-McDermid syndrome has completed all study visits.

ASX health stocks rise in past five days and outpace broader markets Blue chip ResMed slips as US FDA approves weight loss drug Clinical stage immuno-oncology small cap Immutep gains 160%  Morgans healthcare and life sciences expert Iain...

ASX erased yesterday’s gains on Fed chair Powell’s hawkish tilt The RBA has revised its inflation target upward Job seekers’ services stock APM was worst large cap after issuing a warning   The ASX erased yesterday’s gains, down by -0.5%...

ASX closed modestly higher as stocks were up across the board Xero slumped 13pc, despite delivering strong half-year results Optus CEO can’t explain in layman terms the root cause of yesterday’s outage   The ASX rose by 0.2% on Thursday,...

It was a great start to the trading week this Monday for the S&P/ASX 200 Index (ASX: XJO). After a great week last week, the ASX 200 kept the train rolling dow...

ASX health stocks rise in past five days in line with broader markets Mach7 Technologies reports record quarterly sales orders for Q1 FY24 Aroa maintains FY24 revenue growth forecast at 30% after strong Q2 Healthcare and life sciences exp...

We’re coming to you from Perth Town Hall, where the Young Investor Carnival has been held today. It’s an event hosted by the Young Investor Circle, to help educate new investors. You can see interviews with some of the panellists in o...

The S&P/ASX 200 Index (ASX: XJO)'s so-far lucrative month of November continued this Friday. After banking gains on Wednesday and yesterday, the ASX 200 finishe...

ASX lifted 1pc on Friday, up 3pc for the week Neuren, Block Inc, Lendlease, and media stocks were the best gainers FTX founder Sam Bankman-Fried found guilty on all charges   The ASX tracked Wall Street to close 1% higher today. For the w...

Neuren Pharmaceuticals (ASX: NEU) is expecting to receive increasing royalty payments from its US partner Acadia Pharmaceuticals, with sales of the recently launched DAYBUE treatment continuing to surge. The Australian pharmaceutical compan...

In afternoon trade, the S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a very positive note. At the time of writing, the benchmark index is up 1.1% to 6,977.1 points. Four ASX shares that are rising more than most today...

Welcome to our market update, coming to you from the Young Investor Carnival at the Perth Townhall today. The event – held by the organisation, Young Investor Circle, is all about educating those new to investment through panel discussio...

  Neurotech has a clear path for development and commercialisation of NTI164 to treat PANDAS/PANS With no approved therapy for PANDAS/PANS Neurotech is pursing orphan drug designation for NTI164 Results of Neurotech’s phase 1/2 trial inves...

Neuren’s blockbuster drug DAYBUE generates big sales in Q3 Argenica jumps 40pc after releasing preclinical results from Alzheimer’s trial Integral Diagnostics crashes 30pc after conceding more inflationary pressures ahead   Neuren’s DAYBU...

In some much-needed relief, the S&P/ASX 200 Index (ASX: XJO) has given investors a big day of relief. By the end of this Tuesday's session, the ASX 200 had shrugge...

The S&P/ASX 200 Index (ASX: XJO) has once again started the trading week off on the wrong side of the bed. After giving investors relief from the sell-offs we have...

ASX-listed Impedimed Limited Pharmaceuticals (ASX:IDP), Avita Medical (ASX:AVH), and Neuren Pharmaceutical (ASX:NEU) lead in share price increase for 2023 while Lumos Diagnostics (ASX: LDX) tops third-quarter rankings.

The S&P/ASX 200 Index (ASX: XJO) had gotten through a bumpy, but overall positive day of trading this Wednesday. After spending time in both positive and negative territory...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

It's been yet another pleasing day for the S&P/ASX 200 Index (ASX: XJO) this Wednesday, giving ASX shares a three-for-three winning streak for the week thus far. The ASX 200 put...

The S&P/ASX 200 Index (ASX: XJO) is in fine form on Tuesday. In afternoon trade, the benchmark index is up 1.2% to 7,054.2 points. Four ASX shares that have failed to follow the market higher today are listed below. Here's why they a...

The S&P/ASX 200 Index (ASX: XJO) has finally cracked its run of negativity and given investors a positive day today. After falling every single day this week thus far, the ASX 200...

ASX closes higher as Wall Street rebounds and US bond yields retreat on weaker jobs data Lithium miners fall as J.P. Morgan downgrades sector after reviewing lithium price outlook Life 360 and Xero higher as tech sector rallies along with...

If you're in the market for some new ASX shares this month, then it could be worth listening to what analysts at Bell Potter are saying. That's because they have just revealed their favoured picks for October. Two on list this month are...

The S&P/ASX 200 Index (ASX: XJO) has just endured a horror day as investors scramble for the exits amid widespread fears over ASX sales. By the end of today's trading, the ASX 200 ha...

ASX slips to 100-day low as climbing US 10-year bond yields weigh on global markets RBA keeps rates on hold but new governor Michele Bullock hasn’t ruled out further hikes CSL leads healthcare higher after Morgan Stanley puts an overweigh...

With apologies to Charles Dickens, it’s the best of times and the worst of times for wound care house Next Science (ASX:NXS) as it shapes itself up for a renewed market assault under a new CEO. On the positive side of the ledger, the compan...

It's been yet another day of falls for ASX shares and the S&P/ASX 200 Index (ASX: XJO) this Thursday, making it the third of four days this week that have seen losses. The ASX 200 chec...

The S&P/ASX 200 Index (ASX: XJO) has once again given investors a headache this Wednesday, as the index recorded yet another day in the red. Following yesterday's sell-off, the ASX 200...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create uncertainty Fitch Ratings Agency downgraded the credit rating of Ramsay Health Care (ASX:RHC) to BBB- from BBB Botanix Pharmaceuticals expects...

2023 a case of “haves and have nots” for ASX biotech sector as companies with good catalysts lead the pack  Neuren’s results of Phase 2 clinical trial of NNZ-2591 in Phelan-McDermid syndrome due in December Antisense Therapeutics Phase2b t...

Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.47% to 7196.60. Markets @ Midday: Listen here at lunchtime or find all Market Matters Podcasts on Spotif...

It's been another sad day for the S&P/ASX 200 Index (ASX: XJO) this Tuesday. After the rough start to the trading week the ASX 200 gave us yesterday, investors were probably hoping for a rec...

Several ASX companies are undergoing rigorous clinical trials to gain regulatory approval for their cannabinoid products BOD Australia could have the first Schedule 3 CBD product in Australia following positive results from its Phase 2B Ca...

For me, earnings without guidance is a bit like pizza without cheese – little more than cooked tomato paste on flatbread. And I don’t buy it. Macquarie Bank analysts who know more and are paid better for it, said – in their end of season AS...